TICKERNERD
Menu
ELVNELVNHealthcare · Biotechnology

ELVN Stock Forecast: Enliven Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$54
−3.42% on the day

The 12 Wall Street analysts covering Enliven Therapeutics, Inc. hold a median 12-month price target of $74 — +36.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 68 of 100 as at 12 Sept 2026 — in the upper half.

Market cap
$4.0B
Ticker Nerd rank
68 / 100
Median analyst target
$74
Analysts covering
12
Revenue$0.0
Operating income−$37.2M
Net income−$32.5M
Free cash flow−$18.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−9.0%
1M
−7.6%
YTD
+252.6%
1Y
+172.6%
From 52W high
−11.2%
From 52W low
+258.7%
$15
$61
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ELVN stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Enliven Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
68 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
99
Value
88
Quality
78
Volatility
76
Accruals
52
Revisions
49
Growth
45
Issuance
28
Size
27

Momentum (99): The shares have been drifting up relative to others.

Issuance (28): The company has been issuing shares or taking on financing, diluting existing holders.

Size (27): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ELVN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ELVN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$40$60$80Oct 25Jan 26Apr 26Jul 26ELVNHigh $82Median $74Low $64

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says12 analysts
12 Buy0 Hold0 Sell
Low $64Median $74High $82

The green dot is the last close — the median target sits +36.3% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 5 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
18 Aug 2026BarclaysInitiatesOverweight$78
18 Aug 2026MizuhoMaintainsOutperform$62 → $73
18 Aug 2026William BlairInitiatesOutperform—
6 Aug 2026Goldman SachsMaintainsBuy$67 → $80
6 Aug 2026Goldman SachsMaintainsBuy—
6 Aug 2026GuggenheimMaintainsBuy$80 → $78
6 Aug 2026GuggenheimMaintainsBuy—
6 Aug 2026StifelMaintainsBuy—
6 Aug 2026StifelMaintainsBuy$80 → $82
21 July 2026Goldman SachsMaintainsBuy—
21 July 2026Goldman SachsMaintainsBuy$59 → $67
9 July 2026HC Wainwright & Co.MaintainsBuy—
9 July 2026HC Wainwright & Co.MaintainsBuy$56 → $64
1 July 2026StifelMaintainsBuy—
29 June 2026Jones TradingMaintainsBuy—
9 June 2026StifelInitiatesBuy—
2 June 2026MizuhoMaintainsOutperform—
8 May 2026Goldman SachsMaintainsBuy—
26 Mar 2026HC Wainwright & Co.MaintainsBuy—
25 Mar 2026MizuhoMaintainsOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ELVN appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

ELVN vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Enliven Therapeutics, Inc. returned +172.6% against +17.5% for the S&P 500, dividends included.

ELVN vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250300Oct 25Jan 26Apr 26Jul 26ELVNS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ELVN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
2
Fundamentals

Enliven Therapeutics, Inc. (ELVN) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−29.7×

Cheaper than 97% of US stocks

Price / sales
—
Price / book
4.4×

Cheaper than 23% of US stocks

EV / EBITDA
−24.8×

Cheaper than 90% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−15.3%

Higher than 33% of US stocks

Return on assets
−11.0%

Higher than 26% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Enliven Therapeutics, Inc. (ELVN) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Enliven Therapeutics, Inc. has a market value of $4.0B and an enterprise value of $3.1B.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$105.9M.

  • Diluted earnings per share, trailing twelve months: $−1.67.

  • Free cash flow in the twelve months to 30 June 2026: −$67.0M.

  • Shares outstanding: 73.3M.

  • Trailing P/E: −29.7×; forward P/E: −23.2× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Enliven Therapeutics, Inc. employs 67 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

ELVN vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ELVNEnliven Therapeutics, Inc.$4.0B
68
TNGXTango Therapeutics, Inc.$3.9B
41
IOVAIovance Biotherapeutics, Inc.$3.8B
90
RLAYRelay Therapeutics, Inc.$4.0B
71
CELCCelcuity, Inc.$4.1B
27
VKTXViking Therapeutics, Inc.$3.7B
29
MANEVeradermics, Inc.$4.1B
2

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Enliven Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ELVN news & analysis

Enliven Therapeutics to Present at Upcoming Investor Conferences

PRNewsWire · 3 Sept 2026neutral

Enliven Therapeutics announced that its management will participate in upcoming investor conferences, including the Wells Fargo 21st Annual Healthcare Conference, scheduled for Tuesday, Sept. The company is a clinical-stage biopharmaceutical firm focused on developing small molecule therapeutics.

Why it matters — Investor conference participation gives ELVN watchers an opportunity to hear directly from management, which can raise visibility for the company within the investment community.

Enliven Therapeutics: A Clean Active-Site TKI Could Redefine CML Sequencing

Seeking Alpha · 3 Sept 2026positive

Seeking Alpha coverage describes Enliven Therapeutics as a late-stage, well-capitalized biotech with about $895M in cash, funding operations into 2030 and supporting the pivotal ENABLE-2 trial. The article highlights ELVN-001, a selective ATP-competitive inhibitor for chronic myeloid leukemia, citing Phase 1 data showing 61% major molecular response at 80 mg daily with favorable safety and convenience for chronic use in a sequential treatment paradigm.

Why it matters — The article positions ELVN-001's Phase 1 efficacy and safety profile as supporting a differentiated, earlier-line CML opportunity for Enliven, which is relevant to watchers tracking the company's pipeline progress.

Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting

PRNewsWire · 31 Aug 2026positive

Enliven Therapeutics announced it will present data from the ENABLE Phase 1 clinical trial of ELVN-001 in both oral and poster presentations at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting, to be held September 9-12, 2026. The announcement was made by the clinical-stage biopharmaceutical company focused on small molecule therapeutics.

Why it matters — Presenting Phase 1 ENABLE trial data for its lead candidate ELVN-001 at a major hematology conference highlights clinical progress that ELVN watchers would want to track.

Enliven's Lead Drug Could Disrupt The Leukemia Treatment Market, Analyst Says

Benzinga · 18 Aug 2026positive

William Blair initiated coverage on Enliven Therapeutics with an Outperform rating, citing the potential of its lead drug candidate ELVN-001 to reshape treatment of chronic myeloid leukemia (CML).

Why it matters — The analyst initiation highlights growing external confidence in Enliven's lead drug candidate and its potential to disrupt the CML treatment market.

Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update

PRNewsWire · 5 Aug 2026positive

Enliven Therapeutics reported second quarter 2026 financial results and a business update, disclosing positive Phase 1 clinical data for ELVN-001 in chronic myeloid leukemia (CML) with encouraging efficacy and a favorable safety profile. The company also announced alignment with the FDA on key Phase 3 trial design components and reported $895 million in cash, cash equivalents and marketable securities, expected to fund operations into 2030.

Why it matters — The positive Phase 1 data, FDA alignment on the Phase 3 design, and a cash runway into 2030 signal meaningful clinical and regulatory progress for ELVN's lead program and its financial staying power.

FAQ

Frequently asked questions about ELVN stock

What is the ELVN stock price forecast for 2026-2027?

The 12 Wall Street analysts covering Enliven Therapeutics, Inc. have a median 12-month price target of $74, with estimates ranging from $64 to $82. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ELVN stock a buy right now?

Of the 12 analysts covering Enliven Therapeutics, Inc., 12 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Enliven Therapeutics, Inc. 68 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ELVN?

As at 12 Sept 2026, Enliven Therapeutics, Inc. ranks 68 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (99 of 100).

Will ELVN stock go up?

No one can know that. What the data says: the median 12-month target from 12 analysts implies +36.3% from the last close, and Ticker Nerd's factor model ranks Enliven Therapeutics, Inc. 68 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ELVN stock forecast for 2030?

No analyst covering Enliven Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ELVN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $64 to $82 over the next 12 months.

How has ELVN stock performed over the past year?

Enliven Therapeutics, Inc. returned +172.6% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Enliven Therapeutics, Inc. do?

Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for cancer.

What is the latest news on ELVN?

The most recent item we track (PRNewsWire, 3 Sept 2026): "Enliven Therapeutics to Present at Upcoming Investor Conferences". Enliven Therapeutics announced that its management will participate in upcoming investor conferences, including the Wells Fargo 21st Annual Healthcare Conference, scheduled for Tuesday, Sept. The company is a clinical-stage biopharmaceutical firm focused on developing small molecule therapeutics.

Company

About Enliven Therapeutics, Inc.

Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for cancer. The company’s current pipeline centers on precision oncology programs designed to target clinically validated pathways with greater selectivity and improved tolerability. Its lead candidates include ELVN-001, a kinase inhibitor being evaluated for chronic myeloid leukemia, and ELVN-002, a CNS-penetrant HER2 inhibitor being studied in HER2-altered solid tumors such as non-small cell lung cancer. Enliven Therapeutics, Inc. operates in the oncology drug development market, where small molecule inhibitors play an important role in addressing unmet needs across liquid and solid tumors. The company is headquartered in Boulder, Colorado, and is organized around research and early-stage clinical development of targeted cancer therapies.

CEO Mr. Richard A. Fair M.B.A. · 67 employees · United States · https://www.enliventherapeutics.com